Therapy Component Trips Up Lykos’ MDMA At US FDA AdComm For PTSD

 
• By Bridget Silverman
MDMA
Advisory committee members raised several concerns about Lykos' proposed "entactogen." • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers